The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

TDBPP     1-[bis(2,3- dibromopropoxy)phosphoryloxy]- 2...

Synonyms: Tdbp, Tris-BP, Flacavon R, Flammex AP, Zetifex zn, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Zetofex ZN


High impact information on Zetofex ZN


Chemical compound and disease context of Zetofex ZN


Biological context of Zetofex ZN


Anatomical context of Zetofex ZN


Associations of Zetofex ZN with other chemical compounds


Gene context of Zetofex ZN

  • In the case of Tris-BP, GSTP1-1 was much more active in potentiating the mutagenicity [7].
  • Modification of the experimental protocol by performing partial hepatectomy 24 h after the administration of Tris-BP, did not increase the number of GGT+ or glutathione S-transferase-P (GST-P+) positive foci above the control level [17].
  • Because the liver is a major site for bioactivation of Tris-BP to 2BA in vivo, we tested the initiating capacity of Tris-BP in the rat liver in a modified Solt & Farber initiation and promotion system [17].
  • 2. In contrast to the high mutagenicity of Tris-BP and 2BA in Salmonella typhimurium, we were unable to detect an increase in mutation frequency of 2BA on the hprt locus of human TK6 cell line [18].
  • The use of completely deuterated Tris-BP as a metabolic probe revealed that cytochrome P450 and most likely the formation of 2-bromoacrolein (2BA) from Tris-BP is important for the observed genotoxic effects [18].

Analytical, diagnostic and therapeutic context of Zetofex ZN


  1. Children absorb tris-BP flame retardant from sleepwear: urine contains the mutagenic metabolite, 2,3-dibromopropanol. Blum, A., Gold, M.D., Ames, B.N., Jones, F.R., Hett, E.A., Dougherty, R.C., Horning, E.C., Dzidic, I., Carroll, D.I., Stillwell, R.N., Thenot, J.P. Science (1978) [Pubmed]
  2. The genotoxicity of 2-bromoacrolein and 2,3-dibromopropanal. Gordon, W.P., Søderlund, E.J., Holme, J.A., Nelson, S.D., Iyer, L., Rivedal, E., Dybing, E. Carcinogenesis (1985) [Pubmed]
  3. Species differences in kidney toxicity and metabolic activation of tris(2,3-dibromopropyl)phosphate. Søderlund, E.J., Nelson, S.D., von Bahr, C., Dybing, E. Fundamental and applied toxicology : official journal of the Society of Toxicology. (1982) [Pubmed]
  4. Mutagenicity of Tris(2,3-dibromopropyl) phosphate in mammalian gonad and bone marrow tissue. Salamone, M.F., Katz, M. J. Natl. Cancer Inst. (1981) [Pubmed]
  5. Renal carcinogenic and nephrotoxic effects of the flame retardant tris(2,3-dibromopropyl) phosphate in F344 rats and (C57BL/6N X C3H/HeN)F1 mice. Reznik, G., Ward, J.M., Hardisty, J.F., Russfield, A. J. Natl. Cancer Inst. (1979) [Pubmed]
  6. Sister chromatid exchanges and growth inhibition induced by the flame retardant tris(2,3-dipromopropyl) phosphate in Chinese hamster cells. Furukawa, M., Sirianni, S.R., Tan, J.C., Huang, C.C. J. Natl. Cancer Inst. (1978) [Pubmed]
  7. Increased mutagenicity of 1,2-dibromo-3-chloropropane and tris(2,3-dibromopropyl)phosphate in Salmonella TA100 expressing human glutathione S-transferases. Simula, T.P., Glancey, M.J., Söderlund, E.J., Dybing, E., Wolf, C.R. Carcinogenesis (1993) [Pubmed]
  8. Genotoxicity of the flame retardant tris(2,3-dibromopropyl)phosphate in the rat and Drosophila: effects of deuterium substitution. van Beerendonk, G.J., Nivard, M.J., Vogel, E.W., Nelson, S.D., Meerman, J.H. Carcinogenesis (1994) [Pubmed]
  9. Site-specific cell proliferation in renal tubular cells by the renal tubular carcinogen tris(2,3-dibromopropyl)phosphate. Cunningham, M.L., Elwell, M.R., Matthews, H.B. Environ. Health Perspect. (1993) [Pubmed]
  10. Blocking of in vitro DNA replication by deoxycytidine adducts of the mutagen and clastogen 2-bromoacrolein. van Beerendonk, G.J., van Gog, F.B., Vrieling, H., Pearson, P.G., Nelson, S.D., Meerman, J.H. Cancer Res. (1994) [Pubmed]
  11. Mouse skin carcinogenicity tests of the flame retardants tris(2,3-dibromopropyl)phosphate, tetrakis(hydroxymethyl)phosphonium chloride, and polyvinyl bromide. Van Duuren, B.L., Loewengart, G., Seidman, I., Smith, A.C., Melchionne, S. Cancer Res. (1978) [Pubmed]
  12. Metabolism and disposition of the flame retardant tris(2,3-dibromopropyl)phosphate in the rat. Nomeir, A.A., Matthews, H.B. Toxicol. Appl. Pharmacol. (1983) [Pubmed]
  13. Comparative genotoxicity studies of the flame retardant tris(2,3-dibromopropyl)phosphate and possible metabolites. Holme, J.A., Søderlund, E.J., Hongslo, J.K., Nelson, S.D., Dybing, E. Mutat. Res. (1983) [Pubmed]
  14. Metabolic activation of tris(2,3-dibromopropyl)phosphate to reactive intermediates. II. Covalent binding, reactive metabolite formation, and differential metabolite-specific DNA damage in vivo. Pearson, P.G., Omichinski, J.G., Holme, J.A., McClanahan, R.H., Brunborg, G., Søderlund, E.J., Dybing, E., Nelson, S.D. Toxicol. Appl. Pharmacol. (1993) [Pubmed]
  15. Organ-specific DNA damage of tris(2,3-dibromopropyl)-phosphate and its diester metabolite in the rat. Søderlund, E.J., Brunborg, G., Dybing, E., Trygg, B., Nelson, S.D., Holme, J.A. Chem. Biol. Interact. (1992) [Pubmed]
  16. In vitro and in vivo covalent binding of the kidney toxicant and carcinogen tris(2,3-dibromopropyl)-phosphate. Söderlund, E.J., Nelson, S.D., Dybing, E. Toxicology (1981) [Pubmed]
  17. Lack of mammalian mutagenicity of the potent bacterial mutagen tris(2,3-dibromopropyl) phosphate and its metabolite 2-bromoacrolein. van Beerendonk, G.J., Klein, J.C., Tijdens, R.B., Lichtenauer-Kaligis, E.G., Tasseron-de Jong, J.G., Meerman, J.H. Mutat. Res. (1998) [Pubmed]
  18. Metabolism and genotoxicity of the halogenated alkyl compound tris(2,3-dibromopropyl)phosphate. van Beerendonk, G.J., Nelson, S.D., Meerman, J.H. Human & experimental toxicology. (1994) [Pubmed]
  19. Spectrum of mutations in kidney, stomach, and liver from lacI transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate. de Boer, J.G., Mirsalis, J.C., Provost, G.S., Tindall, K.R., Glickman, B.W. Environ. Mol. Mutagen. (1996) [Pubmed]
  20. Comparative studies on nephrotoxic effects of tris (2,3-dibromopropyl) phosphate and bis (2,3-dibromopropyl) phosphate on rat urinary metabolites. Fukuoka, M., Takahashi, T., Naito, K., Takada, K. Journal of applied toxicology : JAT. (1988) [Pubmed]
  21. In vivo and in vitro biological effects of the flame retardants tris(2,3-dibromopropyl) phosphate and tris(2-chlorethyl)orthophosphate. Sala, M., Gu, Z.G., Moens, G., Chouroulinkov, I. European journal of cancer & clinical oncology. (1982) [Pubmed]
WikiGenes - Universities